Determining the cause of acute lower respiratory diseases, such as community acquired pneumonia and exacerbations in chronic respiratory patients.
Providing a sample from the site of infection, allowing for unambiguous diagnostic results within the "golden" hour, enabling directed therapy in a timely fashion.
Assessment of COPD patients admitted with an exacerbation (unpublished).
Early detection of respiratory pathogens in patients with Chronic Respiratory Disease, e.g. CF and COPD.
Easy-of-use and low sampling burden allow for daily or even hourly sampling, enabling health monitoring of the lower respiratory tract and early treatment, avoiding under- or over-treatment and herewith exacerbations.
‘Non-invasive diagnostics of pathogenic bacteria using a breath sampler in children with cystic fibrosis’, K. J. van Aerde, et al., Journal of Breath Research, 2022.
More relevant than ever, safeguarding medical personnel and determining if a patient should be isolated or can go home to recover.
The mere presence of pathogens in conventional samples does not determine contagiousness, however, the presence in aerosols does.
‘SARS-CoV-2 RNA in exhaled air of hospitalized COVID-19 patients’, L. Kurver, et al., Scientific Reports, 2022.
Leave us a message
Xheal Diagnostics B.V. is a start-up company and spin-off of the Radboudumc focussed sampling innovations for the lower respiratory tract. Our proprietary exhaled breath sampling technology enables a timely and better diagnosis of lung infections and hence improves patient care.